The US Food and Drug Administration on Wednesday approved Pfizer's respiratory syncytial virus vaccine for older adults, making it the second shot against the common respiratory disease that can be fatal for seniors.
The CDC's advisory committee is expected to meet in June to discuss the vaccines, including who should receive them and how often. RSV usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalisation. It is estimated to be responsible for 14,000 deaths in adults aged 65 and older in the United States annually, according to government data.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: